GALE Insider Trading Activity and SEC Form 4 Filings
GALE insider trading summary
No open-market insider purchases or sales of Galena Biopharma, Inc. (GALE) have been reported on SEC Form 4 in the past 12 months.
Latest GALE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 20, 2017 | Rudolph Nisi | Director | Sell | $273 (500 @ $0.55) |
| Feb 8, 2017 | Hudson Bay Capital Management LP | 10% Owner | Sell | $2.0M (2,363,441 @ $0.84) |
| Feb 8, 2017 | Sander Gerber | 10% Owner | Sell | $2.0M (2,363,441 @ $0.84) |
| Jun 1, 2016 | Ryan Dunlap | Former Chief Financial Officer | Sell | $277K (126,875 @ $2.18) |
| Feb 12, 2014 | Richard Chin | Director | Sell | $812K (187,500 @ $4.33) |
| Feb 7, 2014 | Rudolph Nisi | Director | Buy | $99K (20,000 @ $4.94) |
| Feb 3, 2014 | Stephen S Galliker | Director | Sell | $1.3M (300,000 @ $4.18) |
| Jan 30, 2014 | Sanford Hillsberg | Director | Sell | $1.4M (250,000 @ $5.41) |
| Jan 30, 2014 | Mark W. Schwartz | EVP & Chief Operating Officer | Sell | $557K (100,000 @ $5.57) |
| Jan 30, 2014 | Richard Chin | Director | Sell | $279K (50,000 @ $5.57) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.